Healthcare
•3753 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3753)
| Company | Market Cap | Price |
|---|---|---|
|
RAPT
RAPT Therapeutics, Inc.
RPT904 is a monoclonal antibody therapeutic, fitting Monoclonal Antibody Therapeutics.
|
$580.48M |
$35.02
+8.79%
|
|
VPG
Vishay Precision Group, Inc.
Medical infusion pump design win indicates participation in the Medical Devices & Biometrics market.
|
$579.10M |
$43.62
-0.18%
|
|
GOSS
Gossamer Bio, Inc.
Inhaled seralutinib represents a drug-delivery platform that concentrates therapy in the lungs to treat pulmonary hypertension, a major differentiator.
|
$573.00M |
$2.52
+3.06%
|
|
AVNS
Avanos Medical, Inc.
The RFA portfolio (ESENTEC, TRIDENT, COOLIEF) places Avanos in the neuromodulation devices category.
|
$572.61M |
$12.34
|
|
VREX
Varex Imaging Corporation
Core Medical Imaging category representing imaging hardware and components used in medical devices.
|
$572.28M |
$13.81
-0.36%
|
|
NUS
Nu Skin Enterprises, Inc.
The Prysm iO and related wellness devices involve medical/biometric device technology.
|
$571.20M |
$11.54
+1.72%
|
|
DBVT
DBV Technologies S.A.
Viaskin Peanut EPIT patch is a drug-delivery platform; DBV Technologies directly develops and commercializes this patch-based immunotherapy.
|
$569.26M |
$20.74
+10.32%
|
|
DNA
Ginkgo Bioworks Holdings, Inc.
Antibody Discovery Platform reflects the antibody-focused tools and services offered.
|
$565.36M |
$9.56
-0.16%
|
|
NPCE
NeuroPace, Inc.
Core product Neuromodulation device (RNS System) delivering brain-responsive, on-demand therapy for drug-resistant epilepsy.
|
$560.40M |
$16.98
-2.13%
|
|
ABSI
Absci Corporation
Absci's core platform is an Antibody Discovery Platform combining AI design with high-throughput wet-lab validation (lab-in-the-loop) for de novo antibody generation.
|
$559.21M |
$3.87
+3.34%
|
|
OFIX
Orthofix Medical Inc.
Core product category covering orthopedic implants and surgical devices, including spinal hardware.
|
$554.89M |
$14.05
-2.43%
|
|
CYRX
Cryoport, Inc.
BioStorage/BioServices-like offerings place Cryoport in the realm of diagnostics/lab services and related bioservices for samples and storage.
|
$552.24M |
$11.05
-1.95%
|
|
MYGN
Myriad Genetics, Inc.
Companion diagnostics—biomarker-based tests that stratify patients for targeted therapies; aligns with Myriad's genetic tests.
|
$550.82M |
$5.92
-1.99%
|
|
REPL
Replimune Group, Inc.
Replimune is oncology-focused biotech developing oncolytic immunotherapies.
|
$549.51M |
$7.03
-3.77%
|
|
STKL
SunOpta Inc.
The company functions as a co-manufacturer and private label partner, providing manufacturing services to brands and retailers.
|
$548.97M |
$4.64
-0.43%
|
|
FULC
Fulcrum Therapeutics, Inc.
Fulcrum's lead asset pociredir is an oral small molecule therapeutic intended to induce HbF in SCD.
|
$548.49M |
$10.13
-2.36%
|
|
KOPN
Kopin Corporation
CR3 medical headset and defense medical imaging/biometric sensing align with Medical Devices & Biometrics.
|
$537.26M |
$3.28
+10.81%
|
|
PRME
Prime Medicine, Inc.
Directly develops gene editing therapeutics (Prime Editing) and the core therapeutic platform, i.e., gene therapy.
|
$535.60M |
$3.98
-0.25%
|
|
EHAB
Enhabit, Inc.
EHAB's core operations are the provision of home health and hospice services directly to patients.
|
$533.26M |
$10.54
-3.21%
|
|
ZIMV
ZimVie Inc.
Dental Equipment—ZimVie directly designs and sells dental hardware used in clinics (implants, imaging, CAD/CAM, etc.).
|
$530.23M |
$18.99
|
|
DSGN
Design Therapeutics, Inc.
Company develops small-molecule therapeutics (GeneTAC) targeting inherited nucleotide repeat disorders.
|
$528.48M |
$9.27
-0.96%
|
|
SLS
SELLAS Life Sciences Group, Inc.
GPS is an oncology-focused therapeutic developed by SELLAS, targeting cancer antigens (WT1) and used as an immunotherapy.
|
$526.49M |
$4.09
-18.10%
|
|
LENZ
LENZ Therapeutics, Inc.
VIZZ is an aceclidine-based eye drop marketed as an ophthalmic drug for presbyopia.
|
$521.67M |
$18.27
+0.74%
|
|
ANNX
Annexon, Inc.
Annexon's lead programs are monoclonal antibody therapeutics (ANX005, ANX009) targeting C1q.
|
$515.37M |
$4.67
-6.87%
|
|
CRMD
CorMedix Inc.
DefenCath is an FDA-approved antimicrobial catheter-lock device marketed by CorMedix.
|
$506.12M |
$6.77
-3.42%
|
|
PRTA
Prothena Corporation plc
Prothena's core assets are monoclonal antibody therapeutics (PRX012, PRX019, PRX123, etc.) across neurodegenerative diseases, including Alzheimer's and other indications.
|
$503.31M |
$9.36
+1.03%
|
|
CERS
Cerus Corporation
Cerus' INTERCEPT Blood System is a medical device platform; primary product is a device used in transfusion safety.
|
$498.42M |
$2.60
-5.11%
|
|
LXRX
Lexicon Pharmaceuticals, Inc.
Lexicon's pipeline includes oral small-molecule therapeutics pilavapadin (LX9211) and LX9851; these are oral small-molecule drugs, a major product category in their portfolio.
|
$497.86M |
$1.38
+7.42%
|
|
OCGN
Ocugen, Inc.
Ocugen's modifier gene therapy platform and lead retinal candidates (OCU400/OCU410) are gene therapy products targeting vision disorders.
|
$494.00M |
$1.69
+4.32%
|
|
MLAB
Mesa Laboratories, Inc.
Clinical Genomics hardware (MassARRAY) is diagnostic equipment used in regulated lab environments, fitting Diagnostic Equipment.
|
$487.92M |
$88.86
+1.08%
|
|
ORGO
Organogenesis Holdings Inc.
Core wound care device category covering Apligraf and Dermagraft, along with barrier products like PuraPly and FortiShield.
|
$480.79M |
$3.79
-4.53%
|
|
ENGN
enGene Holdings Inc.
engGene's core platform is non-viral gene therapy delivery (DDX platform) and its lead asset is a gene therapy product, placing it squarely in Gene Therapy.
|
$476.60M |
$9.34
+1.30%
|
|
SIGA
SIGA Technologies, Inc.
SIGA's core product is TPOXX, a small-molecule antiviral for orthopoxviruses, directly produced and marketed by the company.
|
$471.17M |
$6.58
-0.53%
|
Showing page 17 of 38 (3753 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
